Breaking News: MEDIROM’s Subsidiary, MEDIROM MOTHER Labs, Secures JPY260.3 Million in Series A Funding!
Description:
TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximately USD $1.7 million calculated at an exchange rate of JPY153.64 to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $58.6 million calculated at an exchange rate of JPY153.64 to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre-money valuation of 9 billion yen is approximately multiples of MEDIROM’s current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji.
How This Will Affect Me:
As a shareholder or investor in MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), this announcement is significant as the subsidiary MEDIROM MOTHER Labs Inc. secures JPY260.3 million in Series A funding. This funding can potentially drive innovation and growth within the company, leading to an increase in value for shareholders.
How This Will Affect the World:
The successful funding round for MEDIROM MOTHER Labs Inc. not only showcases the support and confidence of strategic partners and investors but also highlights the potential for advancements in healthcare technologies that can positively impact the world. These investments can lead to the development of new healthcare solutions and technologies that improve patient care and outcomes globally.
Conclusion:
The securing of JPY260.3 million in Series A funding by MEDIROM’s subsidiary, MEDIROM MOTHER Labs, marks a significant milestone for the company and its growth trajectory. With strategic partners and investors showing support, the future looks promising for the development of innovative healthcare technologies that can benefit both stakeholders and the global community.
